Day: January 19, 2021

BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by Athira. In addition, Athira expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.Goldman Sachs & Co. LLC, Jefferies and Stifel are acting as...

HOUSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) — Recruiter.com announced today that its Recruiter.com Video solution is now available on SAP®App Center, the digital marketplace for SAP partner offerings. The solution integrates with SAP® Fieldglass® solutions and helps businesses transform their hiring processes with mobile-friendly capabilities.“The pandemic has accelerated the use of technology in the hiring process for businesses of all sizes,” said Evan Sohn, Chairman and CEO of Recruiter.com. “Now, it’s time to amplify the power of that technology by bringing it into the hiring process at an even earlier stage. While plenty of existing technologies are great substitutes for in-person meetings and live interviews, Recruiter.com Video serves as an ideal replacement for phone screens and first-round interviews.”The integration with SAP...

Company Announcement No. 02/2021Copenhagen, 19 January 2021Fidim S.r.l. (“Fidim”) has acquired more than 90% of the total share capital and voting rights of Athena Investments A/S (“Athena”) following the completion of its voluntary public cash offer dated 19 October 2020 (see Company Announcement No. 22/2020).Consequently, Fidim is entitled to carry out a compulsory acquisition of the shares held by the remaining shareholders of Athena.Simultaneously with the initiation of the compulsory acquisition process, an application is made to Nasdaq Copenhagen A/S (“Nasdaq Copenhagen”) with a request to remove Athena’s shares (ISIN DK0010240514) from trading and official listing at Nasdaq Copenhagen.Reference is made to the attached notice from Fidim for further information on the compulsory acquisition to the minority shareholders of Athena.  The...

Selskabsmeddelelse nr. 02/2021København, 19. januar 2021Fidim S.r.l. (”Fidim”) har erhvervet mere end 90% af den samlede aktiekapital og stemmerettighederne i Athena Investments A/S (”Athena”) efter gennemførelsen af sit frivillige offentlige kontante købstilbud af 19. oktober 2020 (se selskabsmeddelelse nr. 22/2020).Fidim er derfor berettiget til at gennemføre en tvangsindløsning af de aktier, som ejes af de tilbageværende aktionærer i Athena.Samtidig med iværksættelse af tvangsindløsningsprocessen sendes en anmodning til Nasdaq Copenhagen A/S (”Nasdaq Copenhagen”) om at slette Athenas aktier (ISIN DK0010240514) fra handel og official notering på Nasdaq Copenhagen.Der henvises til vedhæftede meddelelse fra Fidim for yderligere information om tvangsindløsning til minoritetsaktionærerne i Athena.BestyrelsenFor yderligere information:Peter...

DENVER, Jan. 19, 2021 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (the “Company”) announced today that Brundage-Bone Concrete Pumping Holdings Inc. (the “Issuer”), a wholly-owned subsidiary of the Company, intends to offer, on a private placement basis, $350.0 million aggregate principal amount of senior secured second lien notes due 2026 (the “Notes”). In addition, the Company expects to amend and restate its existing ABL credit agreement (the “ABL Facility”) to provide up to $125.0 million of commitments. The Issuer’s obligations under the Notes will be guaranteed by the Company, Concrete Pumping Intermediate Acquisition Corp. (“Intermediate Holdings”) and each of the Company’s domestic, wholly-owned subsidiaries that is a borrower (other than the Issuer) under or guarantees the ABL Facility.The Company intends...

NAPLES, Fla., Jan. 19, 2021 (GLOBE NEWSWIRE) — Beasley Broadcast Group, Inc. (Nasdaq: BBGI) (the “Company”), a multi-platform media company, announced that its wholly owned subsidiary, Beasley Mezzanine Holdings, LLC (the “Issuer”), intends to offer $280.0 million in aggregate principal amount of senior secured notes (the “Notes”), subject to market and other conditions, to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States in compliance with Regulation S under the Securities Act.The Notes are expected to be fully and unconditionally guaranteed by the Company and each of the Company’s existing domestic majority owned subsidiaries and certain future material domestic majority owned subsidiaries on...

Efter en genberegning kan det nu oplyses, at det forventede udbytte for nedenstående afdeling vil udgøre 1,60. Det forventede udbytte er vist som kr. pr. andel á 100 kr.Bestyrelsen har besluttet, at udbyttet for 2020 vil være minimumsudlodningen, og denne forventes udbetalt den 10. februar 2021.Sidste dag for handel med afdelingen inklusive ret til á conto udbytte:          5. februar 2021Første dag for handel med afdelingen eksklusive ret til á conto udbytte:       8. februar 2021Forventet dag for hvornår udbyttet vil være til rådighed på depotkonto:      10. februar 2021Det endelige udbytte (minimumsudlodningen) forventes offentliggjort umiddelbart efter bestyrelsens møde den 24. februar 2021, hvor årsrapporten behandles, og godkendt af generalforsamlingen den 24. marts 2021.Eventuelle henvendelser vedrørende denne meddelelse kan rettes...

WATERTOWN, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for its lead product candidate, CFT7455, an orally bioavailable MonoDAC (Monofunctional Degradation Activating Compound) targeting IKZF1/3 for the treatment of hematologic malignancies such as multiple myeloma and non-Hodgkin lymphomas, including peripheral T cell lymphoma and mantle cell lymphoma. The FDA has completed its 30-day safety review and granted approval for the company to proceed with the proposed Phase 1/2 clinical trial for CFT7455.“The clearance...